Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LYT-200 in Relapsed/Refractory AML or High-risk MDS
NCT05829226Phase 1Completed
- Sponsor
- PureTech Health
- Start
- Dec 2022
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of lyt-200 in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (2 arms), sponsored by PureTech Health. Primary endpoints: Incidence of Treatment-Emergent Adverse Events at 1 year and Incidence of Dose Limiting Toxicities at 1 year. Started Dec 2022; status: completed.
02
Drugs
lyt-200
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT05829226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05829226.